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Recommendations in asthma guidelines presuppose that practitioners have the evidence,
information, knowledge, and tools to select inhaler devices appropriate for individual
patients. Randomised controlled trials usually exclude patients with suboptimal inhaler
technique. There is therefore little evidence on which to base inhaler selection in the real
world, where patients often use their inhalers incorrectly. The lung deposition of inhaled
drug varies according to inhaler device, drug particle size, inhalation technique, and
pattern of inspiratory flow. Even with training, not all patients can use their inhalers
correctly and maintain inhaler technique; patients may have inability to handle the inhaler,
strong negative preferences, or natural breathing patterns that do not match their
prescribed inhaler. Therefore, matching device to the patient may be a better course of
action than increasing therapy or training and retraining a patient to use a specific inhaler
device. Several research questions require answers to meet the goal of helping prescribers
make a more informed choice of inhaler type. Is the level of drug deposition in the lungs
a key determinant of clinical short- and long-term outcomes? What should be measured
by a clinical tool designed to check inhaler technique and therefore help with device selec-
tion? If we have a tool to help in individualising inhaler choice, will we achieve better)1224 554588; fax: þ44 (0)1224 550683.
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1238 J. Haughney et al.Table 1 Reasons for poor asthm
1. Wrong diagnosis or confoundin
2. Incorrect choice of inhaler or
 Mixed device types
 Poor training
 Erosion of technique
 Unable to use the recomme
3. Unintentional or intentional n
 Low necessity: patients’ do
 Persistent disease but episo
 Forgetfulness
 High concerns: patients’ co
4. Concurrent smoking
 Relative steroid resistance
5. Comorbid rhinitis
 Associated with worse asthm
6. Individual variation in treatm
7. Undertreatmentasthma outcomes? Do we have to refine inhaler device choice for each individual, or will we
get better outcomes if we select our current best option in light of current knowledge and
apply this on a population level?
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Asthma guidelines recommend individualising inhaled
therapy for each patient, taking into consideration patient
preference, in conjunction with training and regular
monitoring of inhaler technique.1,2 These recommenda-
tions presuppose that clinicians, and other healthcare
providers involved with asthma management, have the
research evidence, information, knowledge, and tools to
select an inhaler device appropriate for each patient.
However, given the confusing array of available devices,
healthcare providers may not know all the key features of
inhalers and their operation, and patients often make
mistakes in using their inhalers.3
An international panel of respiratory physicians, general
practitioners, and academics with an interest in asthma and
inhalation devices was convened in January 2009 by thea control identified at prior IPC
g illness
poor technique
nded inhalation method despit
onadherence
ubts regarding need for therapy
dic symptoms
ncerns about side effects
a control
ent responseInternational Primary Care Respiratory Group (IPCRG) to
discuss the science of inhaler therapy as it needs to be
applied in clinical practice. In particular we aimed to
highlight where further evidence is needed to provide
guidance on inhaler selection in community settings. This
meeting built upon prior IPCRG work on practical ways to
improve asthma control in clinical practice, which noted
inhalation technique was a major issue in achieving asthma
control (Table 1).4,5
Here we review the aspects of inhaler performance and
use in primary care that materially affect outcomes and the
available evidence that exists to guide clinical decisions in
these areas. This review has enabled us to start to identify
what types of further research and technological develop-
ment are needed to meet the goal of helping prescribers to
make more informed choices of inhaler types for their
patients with asthma. Many of the issues related to inhalerRG international meeting.4
e training
Research needed to guide asthma inhaler choice 1239therapy are similar for asthma and chronic obstructive
pulmonary disease (COPD). However, as possible differences
in inhaler therapy between asthma and COPD have not been
studied systematically, COPD is not discussed further here.
Do inhaler device and the way it is used make
a difference?
Reviews of randomised controlled trials comparing inhaler
devices report no difference in efficacy between devices.6e8
However, most of these trials were performed for licensing
purposes and thus were designed to show noninferiority or
equivalence.Of equal importance, patients enrolled in these
studies received training and must have demonstrated good
inhaler technique; those with improper technique were
excluded. The studies, therefore, do not reflect the pop-
ulation of patients using inhalers.
In the real world, patients often use their inhalers
incorrectly (Fig. 1).6,9e14 Efficient inhalation technique was
demonstrated by only 46e59% of patients in the studies39%
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Figure 1 (a) Frequency of critical handling errors made by
patients with asthma and/or chronic obstructive pulmonary
disease when using four different types of dry powder inhalers
(trade names changed to types AeD). The first attempt was
made after patients read the device instructions, and the
second attempt was made after the investigator explained
device handling. Adapted from Schulte et al.13 (b) Percentage
of patients with uncontrolled asthma who failed to use their
pMDIs correctly, as tested with an Aerosol Inhalation Monitor
(AIM, Vitalograph, Vitalograph, Ltd, Buckingham, England).
The second and third tests were performed after instruction on
pMDI technique. Adapted from Hardwell et al.14reviewed by Cochrane et al.9 In a systematic review, the
mean percentages of patients who used their inhalers
without mistakes were 63% for metered dose inhalers
(MDIs); 75% for breath-actuated MDIs; and 65% for dry
powder inhalers (DPIs).6 Errors are made not only in inha-
lation technique but also in the handling of inhaler devices,
such as preparation and positioning.10,12,13 In addition,
healthcare providers may not know how to use inhalers
correctly.10,11 Importantly, poor inhalation technique can
be associated with a marked (up to 50%) decrease in the
amount of drug deposited in the lung. When the adminis-
tered medication is a bronchodilator, the subsequent acute
increase in FEV1 may be lowered by one third if the device
is not used properly.15e17 Furthermore, the number of
errors in inhaler use and inhalation technique has been
correlated with poorer asthma control in patients using
inhaled corticosteroids (ICS).18
Each type of inhaler requires a different inhalation
technique and breathing pattern to achieve optimal
delivery of drug to the lungs. To avoid confusion, it is
argued that inhaler types should not be mixed for an indi-
vidual patient.19,20 Switching of ICS inhaler device without
an accompanying consultation in general practice has been
instituted in some countries to reduce drug costs. Such
a practice may result in loss of asthma control and
increased consultations (Fig. 2),21 possibly because patients
receive no training on how to use their new device.
Recent observational data suggest that, in real life, the
choice of inhaler device is associated with differences in
outcomes.22e24 It is unclear whether these differences arise
because some inhalers and formulations are inherently
‘better’ or more forgiving of poor technique or because of
other patient-related factors.
Targets of inhaler therapy and particle size
effects
The lung deposition of an inhaled drug varies according to
inhaler device, features of inhalation technique, and34.3
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Figure 2 Outcome of asthma treatment during study year 2
for patients whose inhaled corticosteroid device was switched
without an accompanying consultation (switched cohort) and
matched controls: percentages of patients experiencing
successful asthma treatment, partially successful treatment,
and unsuccessful treatment. Reprinted from Thomas et al.21
1240 J. Haughney et al.particle size. Reported lung deposition for different inhaler
devices varies greatly from 4% for beclometasone delivered
by chlorofluorocarbon (CFC)-propellant MDIs to 53% for
extra-fine beclometasone delivered by CFC-free hydro-
flouroalkane (HFA)-propellant MDIs.25 However, variation in
study methods and differences in how the deposition frac-
tion is expressed (eg, nominal dose vs. emitted dose vs. fine
particle dose) make direct comparisons between devices
difficult.6 Moreover, inhaler device technique can substan-
tially affect the amount of drug delivered to the lung.9
Other factors that could influence the level and extent of
deposition include pharyngeal and lower airway anatomy,
severity of obstruction, homogeneity of ventilation, and
hygroscopic properties of the aerosol.
For inhaled asthma therapy to achieve optimal effects,
delivery of drug to the appropriate regions of the lung
should be maximised and deposition of drug in the
oropharynx minimised. Deposition in the large and con-
ducting airways (down to branch 16 of the bronchial tree)
may be preferred for bronchodilators. These agents, most
commonly b2 agonists, will have an effect if deposited in
these airways because there are b2 receptors present in
conjunction with smooth muscle (Fig. 3).26e28 Instead,
a more uniform lung distribution may be preferred for ICS
to also reach the smaller peripheral airways, important
sites of airway inflammation in asthma.29,30
Particles will deposit in different regions of the lungs
depending on their size and the speed of the patient’s
inhalation.31 Overall, smaller inhaled particle sizes are
better able to be distributed throughout the lungs and
reach the distal airways.32 In theory, particles <1 mm can
reach the peripheral airways, where they will have some
local clinical effect. Given the heterogeneous ventilation of
the lungs of people with asthma, and the differing particle
sizes of different therapies (ICS and b2 agonists), differen-
tial deposition of these drugs might result. The clinical
consequences of such a non-homogenous distribution are
unclear and need further investigation.
Results of recent studies suggest that delivering ICS with
smaller particle formulations is associated with better
outcomes.33,34 However, it is difficult to dissociate dose and
deposition, and further studies are needed.35 These
formulations provide better lung deposition with possibly
improved efficacy and greater systemic delivery because ofM
3
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Figure 3 Location of targets for bronchodilators. Adapted
from Carstairs et al.,26 Mak and Barnes,27 and Jeffery.28improved pulmonary delivery as well as reduced impaction
in the oropharynx. Although small particles (w1 mm) have
a greater potential to be exhaled (approximately 10% of the
dose), this is counterbalanced by high pulmonary deposi-
tion (60%), and the net effect is that oropharyngeal depo-
sition is reduced (30%).36 To maintain similar efficacy and
safety it is, therefore, recommended that the dose of these
products is halved.36,37 Particles 1e5 mm will reach the
large and conducting airways where they will exert their
clinical effect and be subsequently absorbed from the
lungs. Particles >5 mm tend to settle into the mouth and
oesophageal region, where they produce no clinical effect
but can potentially produce both local side effects and
systemic side effects after gastrointestinal absorption.Key factors affecting delivery of drug to the
lungs
Metered dose inhalers require slow and deep
inhalation as well as co-ordination
Exhalation to functional residual capacity or residual volume
should precede the inhalation.38 This translates to a full
inspiratory vital capacity, which is required for all MDIs and
DPIs. For MDIs, although good coordination is required and
can be a problem for some patients, the most important
aspect of inhalation technique is a slow (<60 L/min) and
deep inhalation.39e41 In practice this translates to a full
inhalation that lasts for 2 s (small child) to 5 s (adult). Failure
to use a slow and deep inhalation is the most common
mistake made by patients using an MDI and is more common
than failure of coordination.33,42,43 Ideally, the actuator
should be pressed at the start of the inhalation; however, we
now know that the split-second coordination of actuation
and inhalation is less critical if the inhalation is slow39 and
especially if actuation occurs after the start of inhalation.41
Moreover, breath holding to facilitate sedimentation at the
end of the inhalation is less critical if the inhalation is slow.39
A faster inhalation rate increases the likelihood of
oropharyngeal deposition with an MDI.32 Larger particles
tend to settle in the oropharyngeal region with fast inha-
lations, whereas smaller particles (1.5 mm) show little
difference in lung and oropharyngeal deposition whether
the inhalation is fast or slow.32
Dry powder inhalers require a rapid and forcible
inhalation
Before inhalation, the formulation of all DPIs has no
potential for lung deposition. It is the patient’s inhalation
that transforms the powder in a DPI into an emitted dose of
particles with the appropriate characteristics for deposition
in the lungs. When a patient inhales through a DPI, turbu-
lent energy inside the device is created by the pressure
drop (ΔP) that results from the interaction between the
patient’s inhalation flow (Q) and the internal design of the
DPI, which translates into a resistance to airflow (R). Since
the turbulent energy is represented by the relationship
ODPZQ R,44 inhalation flow should not be viewed in
isolation when comparing DPIs. It is, however, correct to
Research needed to guide asthma inhaler choice 1241refer to inhalation flow with regard to one type of DPI
because the resistance will not change.
For each inhaler there is a minimum energy, hence
inhalation flow, required to provide efficient disaggregation
of the formulation. The minimum inhalation flow, while not
clearly defined for each device, is important because there
is the potential for a patient to receive no dose. In general,
very young and elderly patients and those experiencing
a severe exacerbation may not be able to generate inha-
lation flow sufficient to create turbulent energy that
produces a dose reaching the lungs from some devices.
However, it should be stressed that there are some stable
patients of any age and severity of obstruction who may not
be capable of generating sufficient energy inside their DPI,
and so this needs to be checked routinely for all patients.44
When a patient inhales through a DPI containing doses
stored inside the device (either in a reservoir or as single-
dose blisters), disaggregation of the powder occurs almost
immediately as the dose leaves the device. Fig. 4 depicts two
possible inhalation profiles generated through the same
device by a patient, an ideal profile and a more usual
profile.45 Superimposed onto these profiles is when the dose
would leave a reservoir or blister DPI and a capsule DPI. It is
evident that the rate of increase in flow (and hence turbulent
energy)will be greater, and the disaggregation of the powder
inside the DPI more efficient, for the patient who generates
the ideal inhalation profile. Failure to use a fast inhalation
from the start through a DPI results in the emission of
particles that are too big to be deposited in the lungs and so
the dose is deposited in the oropharynx and subsequently
swallowed.46 If the inhalation is too fast, which is possible for
a DPIwith a low resistance, the powdermay not disaggregate
before it leaves the inhaler. This, as well as the particle’s
momentum in a fast moving airstream, will lead to greater
deposition in the oropharynx.
For some DPIs, a powder-containing capsule is loaded
into the device by the patient, and the dose has to be
emptied from the DPI by the inhalation manoeuvre. Inha-
lation volume is, therefore, another important consider-
ation for capsule DPIs, as pictured in Fig. 4. It is for this
reason that the patient information leaflet for these DPIsDose emission 
from reservoir/ 
blister type DPI 
Time 
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Figure 4 Schematic depicting the relationship between
particle emission rate from a dry powder inhaler (DPI; capsule
& reservoir/blister type) and patient inhalation profiles that
are usual vs. ideal for DPI dose emission. Actual shape will vary
with device used. Adapted with permission from Chrystyn and
Price.45directs patients to use two inhalation manoeuvres per
dose.
Optimal dose emission from a DPI, therefore, depends
on the combination of inhalation volume, inhalation flow,
acceleration rate, and the inhaler. The acceleration of the
inhalation flow (at the start of inhalation), whilst the most
important factor, correlates to peak inhalation flow when
the inhalation starts with a fast acceleration.46 In vitro, the
fine particle dose is increased at higher flow rates.47,48 As
a corollary, total lung deposition in vivo is greater with
faster inhalation rates, although the fast inhalation
required by DPIs results in substantial oropharyngeal
deposition even at higher rates.49,50 Combining all the
information in Fig. 4 highlights that the generic instruction
to a patient using a DPI should be to “inhale as deep and
hard as possible, from the start of the inhalation and for as
long as you can.”
Thecombinedeffect ofdifferentflows, acceleration rates,
and inhalation volumes need to be studied in ‘real life’ situ-
ations. Some limited studies have been reported using the
electronic lung.51e53 However, the electronic lung involves
the use of a holding chamber, and patients in these studies
were highly trained to use each DPI and excluded if they could
not use theDPIs after training.There is thereforeaneed for ex
vivo methods to research dose emission from real life inhala-
tion profiles. This should include different strengths and
formulations in the same inhaler device, because the effect of
any changes to these factors is not known.Optimising inhaler therapy
Table 2 summarises the key points regarding the inhalation
manoeuvre required when using MDIs and DPIs. Before per-
forming each inhalation manoeuvre, patients should be
instructed to adhere to themanufacturer’s instructionon the
preparation of the dose. Failure to perform this correctly
could result in no dose being received irrespective of the
inhalation manoeuvre. Confirming proper inhaler technique
is an essential step in optimising drug delivery to the lungs.
Verbal training in proper inhaler technique, both as a sole
measure and coupled with individualised instruction in self-
management of asthma, improves outcomes for patients
with asthma, in part because of improved compliance.54e56
Moreover, regular assessment and reinforcement are
needed to maintain handling and inhalation technique.10
For patients who cannot coordinate actuation and
inhalation with an MDI, switching to a breath-actuated MDI
may be a solution.15 However, choice of pharmacologic
therapy may be limited and the unaccustomed delivery may
cause (a temporary) cough. The use of a spacer reduces
oropharyngeal deposition and can as much as double lung
deposition57 by overcoming actuation/coordination diffi-
culties but is the option least preferred by patients.12 On
a practical note, both small and large spacers reduce
oropharyngeal deposition.58
For DPIs, a prolonged fast inhalation from the start is
important. This can be checked visually and in part with the
use of an In-Check Dial (Clement Clark International, Har-
low, Essex, UK), to ensure that the patient can generate
a minimum effective flow, which at present is universally
accepted as 30 L/min. This meter is limited in that firstly,
Table 2 Summary of the optimal inhalation manoeuvre and key points regarding metered dose inhalers and dry
powder inhalers.
Metered dose inhalers (MDIs) Dry powder inhalers (DPIs)
Inhalation technique:
1. exhale gently as fully as possible,
2. begin to inhale and
3. actuate the dose,
4. continue with slow (<60 L/min) and deep
inhalation over 2 s (child) to 4e5 s (adult),
5. hold breath for 10 s, or as long as possible.
 Ideal co-ordination calls for dose release
(actuation) at start of inhalation.
 Good co-ordination is less critical if the
inhalation is slow, but the dose has to be
released after the start of the inhalation.
 Too fast an inhalation increases the likelihood
of oropharyngeal deposition.
 Patients with poor coordination of actuation
and inhalation can be switched to a breath-actuated MDI.
 MDIs can be used with spacers, large or small, although
spacers score low in patient preference.
Inhalation technique:
1. exhale gently as fully as possible,
2. inhale sharply: as fast and as deeply as possible,
3. hold breath for 10 s, or as long as possible.
 DPIs are breath-actuated and require adequate acceleration
on inhalation: the patient must inhale deeply and forcibly
at the start of the inhalation.
 If the patient does not inhale fast enough or long enough:
B Not all the dose is emitted;
B Particles generated are too big to enter the lungs,
resulting in increased oropharyngeal deposition.
 If the dose is supplied in a capsule then two inhalations are
required to empty the dose.
 DPIs should not be prescribed to patients with insufficient
inspiratory effort, including children <5 years old and
the elderly.
 DPIs are sensitive to moisture: must store in a dry place
and avoid exhaling through the inhaler.
1242 J. Haughney et al.testing is not available for all DPIs, and secondly, it will not
give an indication of the acceleration rate. If the patient’s
natural inhalation is too fast through a particular DPI, then
switching them to a DPI with a higher resistance will reduce
the speed of their inhalation. This should improve drug
distribution in the lungs and limit oropharyngeal impaction.
Individualising inhaler device choice
A choice of possible inhaler devices is defined first by
choice of drug, device availability, and any relevant reim-
bursement restrictions. Consideration of patient age or
ability to use the inhaler may help further refine the list as,
for example, children <5 years old and some elderly
patients should not be prescribed DPIs because they cannot
generate sufficient inspiratory flow. At this point, the
prescriber may still be left with several choices of inhaler
devices. How best to proceed?
One review of inhaler technique after training concluded
that there is no difference in the ability of patients to use
DPIs or MDIs.6 However, even with training, not all patients
can use their inhalers correctly; this is true for both MDIs
and DPIs.12,59 In practice there are indications that patient
preferences for devices vary and, furthermore, that pref-
erence is linked to ability to perform good inhaler tech-
nique, and ultimately this may influence compliance.12,13
Most patients inhale too fast with an MDI,42,43 and many
inhale too slowly with a DPI.60
These findings suggest that not all patients can master
the proper technique for each type of inhaler and, in
addition, that patients may have natural inspiration
patterns that do not match their prescribed inhaler.
Therefore, rather than training and retraining a patient to
use a specific inhaler device, a better course of action
could be to match a device to the patient. In other words,
instead of insisting that patients use a particular device, we
should try to match device with their behaviour. Followingthis logic, the ideal patient to use an MDI is a patient who
tends to use slow deep inhalations, whereas the ideal
patient to use a DPI is one who can easily perform a rapid,
deep, and prolonged inspiration.
We need a clinical tool to characterise a patient’s
inhalation pattern, check inhaler technique, and enable
a match with an inhaler device; this tool should be inex-
pensive and easy to use.
Furthermore, we need more complete information on
inhaler device types. For each MDI, information should
include the maximum rate and minimum length of inha-
lation to achieve good lung deposition. For DPIs, research
is required to define the minimum inhalation flow for
each type of device and the effect of the initial accel-
eration of the inhalation flow. This is important because
there is the potential for patients to receive no dose into
their lungs if they do not inhale fast enough through
a DPI. This information could then be matched with
information generated by the clinical tool to individualise
inhaler choice.
Finally, it would be useful to better standardize the way
devices and drug-device combinations are studied and the
way study results are reported to health authorities and
physicians. This would facilitate the understanding of
technical and delivery/deposition characteristics, optimal
inhalation technique, ease of use, and patient preference.
Conclusions
Inhaler technique is an important factor in achieving
adequate asthma control; increasing or adding treatment is
not a substitute for adequate inhaler technique.
Key questions requiring further research are the
following:
1. To what extent is the level of lung deposition a key
determinant of clinical short- and long-term outcomes?
Research needed to guide asthma inhaler choice 1243Do different drugs require different levels of
deposition?
2. Do devices that are easier to use produce better
outcomes in well-conducted studies?
3. What should be measured by a clinical tool designed to
check breathing pattern and/or inhaler technique?
4. If we have such tools to check breathing pattern, check
inhaler handling technique, and help in individualising
inhaler choice, will their use in influencing inhaler
device choice provide better maintenance of good
inhaler technique and better asthma outcomes? Do we
have to refine inhaler device choice for each
individual?
5. Or, alternatively, will we get better outcomes if we
systematically select the device that we believe
represents the best or the least bad option in light of
current knowledge and apply this on a population level?Conflict of interest
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